title: Long-term outcome of adalimumab therapy for ulcerative colitis with intolerance or lost response to infliximab: a single-centre experience.
abstract: BACKGROUND
  Adalimumab may be effective in inducing remission in patients with mild-to-moderate ulcerative colitis who had secondary failure to infliximab.
  
  
  OBJECTIVE
  To evaluate long-term efficacy and safety of adalimumab in patients with ulcerative colitis who previously responded to infliximab, and then lost response or became intolerant.
  
  
  METHODS
  We report our single-centre experience in 13 patients. The patients received a loading dose of 160 mg of adalimumab subcutaneously in week 0, followed by 80 mg at week 2 and then 40 mg every other week starting at week 4. The primary efficacy measure was the proportion of patients on adalimumab therapy during the study.
  
  
  RESULTS
  Median duration of follow-up was 42 weeks (range, 10-100). The mean number of adalimumab infusions was 21 (range, 5-50). The probability of maintaining adalimumab was 92.3%, 84.6%, 60.6% and 32.5% at 1, 3, 6 and 23 months respectively. Six of 13 patients (46.2%) underwent colectomy during the study. No serious toxicities occurred in the study.
  
  
  CONCLUSIONS
  Adalimumab is well-tolerated and may be effective in maintaining clinical remission in a subgroup of patients with ulcerative colitis and lost response or intolerance to infliximab, potentially avoiding colectomy in about half of the patients.
authors.affiliation: Inserm, U724, and Department of Hepato-Gastroenterology, University Hospital of Nancy, Vandoeuvre-les-Nancy, France.
authors.forename: A
authors.initials: A
authors.lastname: Oussalah
authors.forename: C
authors.initials: C
authors.lastname: Laclotte
authors.forename: J-B
authors.initials: JB
authors.lastname: Chevaux
authors.forename: M
authors.initials: M
authors.lastname: Bensenane
authors.forename: A
authors.initials: A
authors.lastname: Babouri
authors.forename: A-A
authors.initials: AA
authors.lastname: Serre
authors.forename: T
authors.initials: T
authors.lastname: Boucekkine
authors.forename: X
authors.initials: X
authors.lastname: Roblin
authors.forename: M-A
authors.initials: MA
authors.lastname: Bigard
authors.forename: L
authors.initials: L
authors.lastname: Peyrin-Biroulet
mesh_terms: D000068879:Adalimumab; D000293:Adolescent; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D013223:Statistics as Topic; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069285:Infliximab; D000068879:Adalimumab